---
document_datetime: 2026-01-20 12:08:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/degevma-epar-all-authorised-presentations_en.pdf
document_name: degevma-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7939633
conversion_datetime: 2026-01-20 20:35:24.883962
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength   | Pharmaceutical form    | Route of administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/25/1985/001 | Degevma           | 120 mg     | Solution for injection | Subcutaneous use          | vial (glass)          | 1.7 ml (70 mg/ml)         | 1 vial      |
| EU/1/25/1985/002 | Degevma           | 120 mg     | Solution for injection | Subcutaneous use          | vial (glass)          | 1.7 ml (70 mg/ml)         | 3 vials     |